Adoption of Oral Weight-Loss Drugs Could Be Limited

 The FDA approved an oral version of Wegovy this week, creating a buzz in the weight-loss drug market. But the oral forms of GLP-1s are still likely to pose little risk to the market share of injectables, say KeyBanc analysts. "We think patients on current injectable Wegovy could be reluctant to change (and doctors may not be motivated to change their rx)," the analysts say. The pills could have a market among needle-phobic patients and in areas where cold chain storage is unavailable. But gastrointestinal side effects and less weight loss potential will prevent widespread adoption of oral forms, the analysts say.

https://www.morningstar.com/news/dow-jones/202512243264/adoption-of-oral-weight-loss-drugs-could-be-limited-market-talk